Navigation Links
Monogram Announces 2008 Second Quarter Financial Results
Date:7/29/2008

al approach and products by pharmaceutical and biotechnology companies; our estimate of the size of our markets; our estimates of the levels of demand for our products; the impact of competition; the timing and ultimate size of pharmaceutical company clinical trials; whether payers will authorize reimbursement for our products and services and the amount of such reimbursement that may be allowed; whether the FDA or any other agency will decide to further regulate our products or services, including Trofile; whether existing levels of reimbursement will be reviewed and reduced by third party payers, including Medicare; whether the draft guidance on Multivariate Index Assays issued by FDA will be subsequently determined to apply to our current or planned products; whether we will encounter problems or delays in automating our processes; the ultimate validity and enforceability of our patent applications and patents; the possible infringement of the intellectual property of others; whether licenses to third party technology will be available; whether we are able to build brand loyalty and expand revenues; restrictions on the conduct of our business imposed by the Pfizer, G.E. and other debt agreements; the impact of additional dilution if our convertible debt is converted to equity; and whether we will be able to raise sufficient capital in the future, if required. For a discussion of other factors that may cause actual events to differ from those projected, please refer to our most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission. We do not undertake, and specifically disclaim any obligation, to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.

PhenoSense, PhenoSenseGT, Trofile, HERmark and VeraTag are trademarks of Monogram Biosciences, Inc. Hercept
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Monogram Announces First Medicare Payment for Trofile(TM)
2. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
3. Monogram Biosciences Announces Immediate Availability of Enhanced Sensitivity Trofile(TM) HIV Tropism Assay
4. Monogram Biosciences Collaborates with Gilead Sciences for Elvitegravir Phase III Studies
5. Monogram Announces Commercial Availability of the HERmark(TM) Breast Cancer Assay
6. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
7. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
8. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
9. HEI, Inc. Announces Sale of RFID Division Assets
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
11. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 Padre Murphy's and ... supporter of Pro Player Health Alliance (PPHA). The ... Murphy's in getting everyone, including NFL greats, treated for obstructive ... the leading groups supporting the cause in the valley. The ...
(Date:1/22/2015)... 23, 2015 Angelweddingdress is a famous wedding ... its customers to follow it on Facebook, Twitter, and Pinterest. ... Day gift. Angelweddingdress draws a lottery every week. , Moreover, ... Feb. 28, 2015. Click Angelweddingdress homepage for more ...
(Date:1/22/2015)... 22, 2015 The federal court overseeing thousands ... District Court, Southern District of West Virginia has upheld a ... proceeding’s first bellwether trial. In an Order dated January 21st, ... after finding that C.R. Bard had not proven a miscarriage ...
(Date:1/22/2015)... January 22, 2015 Thousand of GranuFlo ... Care recalled its GranuFlo and NaturaLyte dialysis concentrates continue ... in U.S. District Court, District of Massachusetts, Bernstein Liebhard ... the Court has remanded a case filed by the ...
(Date:1/22/2015)... 22, 2015 Carinsurancesavings.biz has released a new ... and dismemberment insurance . , Purchasing an accidental death ... very advantageous. This type of rider provides benefits if the ... be considered a lesser form of life insurance. , ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
... KENNETT SQUARE, Pa., Aug. 19 Genesis HealthCare ... today announced that 16 of its Centers have been recognized ... presented by the American Health Care Association and National Center ... living centers from across the nation applied for the quality ...
... Sometimes that means trying some risky behaviors. ... cocaine, will be studied in their adolescent years. Researchers ... using drugs, having sex or engaging in delinquent behaviors, and ... The study will also closely follow the cognitive ...
... University of Leicester has revealed new ways to spot ... prestigious British Medical Journal , Santiago Moreno and ... the reporting of clinical trials which potentially form the ... show what mathematical adjustments can be made to remove ...
... chronic liver disease characterized by progressive inflammation and destruction ... usually leading to biliary cirrhosis, portal hypertension and liver ... a common cause of adult cholestatic liver diseases and ... in U.S. adults. At least 70% of PSC ...
... , Editorial is a Call to ... Research indicates that the social stigma that surrounds lesbian, gay, bisexual, ... as substance use, risky sexual behaviors, eating disorders, suicidal ideation, and victimization. ... Health calls on clinicians and health researchers to lead the charge ...
... CARDIFF, Calif., Aug.19 Rapi d ... plans to provide services to the medical cannabis industry. With ... the state of California, Rapid Fire Marketing has entered the ... to this newly-emerged industry, which includes medical doctors and cannabis ...
Cached Medicine News:Health News:Sixteen Genesis HealthCare Centers Receive Prestigious Award for Continuous Quality Improvement in Long Term Care 2Health News:Sixteen Genesis HealthCare Centers Receive Prestigious Award for Continuous Quality Improvement in Long Term Care 3Health News:Longitudinal study investigates cocaine's impact on adolescent development 2Health News:Study finds adverse effects in treatment for primary sclerosing cholangitis 2Health News:Confronting Health Disparities Among Lesbian, Gay, Bisexual and Transgender Youth 2Health News:Confronting Health Disparities Among Lesbian, Gay, Bisexual and Transgender Youth 3Health News:Rapid Fire Marketing Enters Medical Cannabis Business 2Health News:Rapid Fire Marketing Enters Medical Cannabis Business 3
(Date:1/23/2015)... Pa. , Jan. 23, 2015  MedScope ( www.medscope.org ... been nominated for a 2015 Connected World ... Emergency Response System (mPERS), that can be used anywhere, ... technology partner.  In nominating MedScope, ...
(Date:1/23/2015)...  Pete Rose, baseball,s all-time hits leader, is the new spokesperson ... Ducere Pharma has announced. "Pete,s a Hall of ... him on board with Myoflex," said Ducere Pharma Chief Executive ... who is known across all generations. The passion and intensity ...
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), ... I trial of Lixte,s lead compound, LB‑100, is being conducted, ... John S. Kovach , M.D., the founder and President ... be completed at a single site. Accrual of patients, however, ...
Breaking Medicine Technology:MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2Pete Rose bets on Myoflex to relieve aches and pains 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... BOSTON and RIDGEFIELD, Conn., Oct. 30, 2010 Boehringer ... Ib study, SOUND-C1, that showed the combination of two ... BI 201335 and the polymerase inhibitor BI 207127, with ... quantifiable levels in HCV treatment-naive patients. The regimen did ...
... 29 AVANIR Pharmaceuticals, Inc. (Nasdaq: ... and Drug Administration (FDA) has approved NUEDEXTA™ (dextromethorphan ... treatment for pseudobulbar affect.   NUEDEXTA ... (PBA).  PBA occurs secondary to a variety of ...
Cached Medicine Technology:Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon 2Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon 3Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon 4AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™ 2AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™ 3AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™ 4AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™ 5AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™ 6
... Precision Hand Instruments were developed in surgeon's ... while still having an instrument with the ... the fear of the bending or breaking. ... manufactured to conform to the surgeon's hand. ...
... Precision Hand Instruments were developed in surgeon's ... while still having an instrument with the ... the fear of the bending or breaking. ... manufactured to conform to the surgeon's hand. ...
... were developed in surgeon's desire to have ... an instrument with the strength to maneuver ... the bending or breaking. Arthrotek Hand Instruments ... to the surgeon's hand. This new generation ...
... Stryker Universal ACL Instrumentation System has ... a variety of anterior cruciate ligament ... Universal ACL Instrumentation system and endoscopic ... obtain more reproducible anatomical graft placement ...
Medicine Products: